google-site-verification: googlec7193c3de77668c9.html

NHS patients in England can have life-saving heart drug tafamidis

About 1,500 people in England with ATTR-CM could now be eligible for the treatment.

This rare heart condition typically starts to show in adulthood and gets worse over time as the heart tissue thickens and stiffens.

Its symptoms include:

  • shortness of breath

  • palpitations and abnormal heart rhythms

  • ankle swelling, fatigue, fainting and chest pain

Ultimately, it can cause heart failure.

Prof Simon Ray, national clinical director for heart disease at NHS England, said: ”A first of its kind, tafamidis will give those living with this rare progressive condition new hope.

“This pioneering drug is just one example of the NHS delivering on its commitment to ensure patients across the country have access to the latest and most effective treatments to help significantly improve their quality of life.”

The list price for a packet of 30 capsules of the drug is about £10,000, but Pfizer has a commercial agreement for NHS use which will be less, although the cost has not been made public.


Source link

Advertisements

See also  Research suggests CBN shows promise for treating neurological disorders

Check Also

COVID fatigue linked to reduced brain blood flow

[ Credit: Unsplash/CC0 Public Domain Playing with your children or meeting a friend for coffee …

Research reveals major impact of climate change on skin health worldwide

[ Credit: Jimmy Liao from Pexels More than 40% of countries worldwide have reported climate-related …

Long‑acting medicines could make daily tablets a thing of the past for some patients

[ Credit: Unsplash/CC0 Public Domain For millions of people around the world, managing a long-term …

Leave a Reply

Available for Amazon Prime